MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Tarenflurbil

CAS No. : 51543-40-9

MCE 站：Tarenflurbil

产品活性：Tarenflurbil ((R)-Flurbiprofen) 是 Flurbiprofen 的 R 型对映体，Tarenflurbil ((R)-Flurbiprofen) 抑制 [³H]9-cis-RA 结合到 RXRα LBD，IC₅₀ 为 75 μM。

研究领域：Metabolic Enzyme/Protease  |  Autophagy

作用靶点：RAR/RXR  |  Autophagy

In Vitro: Tarenflurbil ((R)-Flurbiprofen) can significantly reduce Aβ secretion, but at the same time, increases the level of intracellular Aβ. The binding between [³H]9-cis-RA and RXRα is competitively inhibited by both unlabeled (R)-Flurbiprofen and 9-cis-RA. (R)-Flurbiprofen can interfere with the interaction between RXRα and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases Tarenflurbil ((R)-Flurbiprofen)’s reduction of Aβ secretion. Tarenflurbil ((R)-Flurbiprofen) treatment significantly increases the levels of intracellular Aβ species. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), Tarenflurbil ((R)-Flurbiprofen) affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing.

In Vivo: Effects of the early and late onset of treatment with Tarenflurbil ((R)-Flurbiprofen) are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapsing-remitting (RR)-EAE. Tarenflurbil ((R)-Flurbiprofen) completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of Tarenflurbil ((R)-Flurbiprofen) are comparable to those of Fingolimod (FTY720, 0.5 mg/kg/day), which is used as the positive control. Tarenflurbil ((R)-Flurbiprofen) also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  Clinical Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Endoplasmic Reticulum Stress Compound Library  |  Retinoic acid  |  Bexarotene  |  AM580  |  Talarozole  |  CD437  |  Fenretinide  |  Isotretinoin  |  AGN 193109  |  Magnolol  |  AGN 194310  |  Tamibarotene  |  Adapalene  |  TTNPB  |  UVI 3003  |  AR7  |  LG100268  |  Peretinoin  |  AGN 195183  |  Palovarotene  |  Tazarotene  |  Acitretin  |  BMS493  |  CD3254  |  Ch55  |  LY2955303  |  PA452  |  9-cis-Retinoic acid  |  Oxybenzone  |  AC-55649  |  LG-100064

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。